As with any medical or dietary treatment, following a VLCD may cause some side effects or temporary symptoms as your body adjusts. These effects are usually mild and short-lived, but it’s important to be aware of them and to report any that persist or cause concern to your GP.
You will also be provided with practical tips on preventing and managing these side effects during throughout the TDR phase. Your Diabetes Practitioner is also there to support you, with assistance from our clinical team as needed.
If you experience any side effects that cause concern while on VLCD report them to your GP / medical team / A&E depending on severity. Remember to prioritise the advice received from them and to let your Diabetes Practitioner or our Patient Support Team know as soon as possible so next steps can be discussed regarding the programme.
Rapid weight loss can have significant benefits for people with type 2 diabetes, but it can also affect your gallbladder. Please read this guide carefully to help you make an informed decision before starting the programme.
The gallbladder is a small organ located under the right side of your ribcage. It stores bile, a digestive fluid that helps break down fats. Problems with the gallbladder are sometimes called biliary disease, which can include gallstones and inflammation.
During the TDR phase of the programme, rapid weight loss (more than 2 lb or 1 kg per week) may occur. While long-term weight loss generally reduces the risk of gallstones, rapid weight loss can temporarily increase the risk:
There are few studies measuring the risk of biliary disease during very low‑calorie diets. One study found that about 1 in 10 people developed gallstones after a 16‑week very‑low‑calorie diet¹. This risk is similar to that seen with medically supervised weight‑loss injections, such as Wegovy, Ozempic, or Mounjaro².
People with a higher starting weight, greater weight loss, or elevated blood triglycerides (a type of fat in the blood) are at increased risk of developing biliary disease.
In some cases, ursodeoxycholic acid, a prescription medication, may be used to reduce gallstone formation. However, there is limited evidence to support its use 3.
If you are unsure whether you are at high risk, or if you already have a diagnosis of gallstones, discuss this with your GP. Together, you can decide whether proceeding with a very low calorie diet, or trying a slower weight loss approach, is best for you.
If pain is severe, you have a fever, or are vomiting, seek urgent medical help (visit A&E or call 999).
If gallstone symptoms occur during the TDR phase, you will need to stop TDR. Our clinical team will advise on the safest next steps, which may include continuing the programme with healthy eating support or, in some cases, discharge.
Rapid weight loss can be an effective step in managing type 2 diabetes, but it is important to understand the risks. Discuss your options with your GP or diabetes team, and consider all available weight loss strategies to choose the safest approach for you.
Sources:
1 Yang H, Petersen GM, Roth MP, Schoenfield LJ, Marks JW. Risk factors for gallstone formation during rapid loss of weight. Digestive Diseases and Sciences. 1992; 37(6):912-8. doi: 10.1007/BF01300390
2 He L, Wang J, Ping F, et al. Association of Glucagon-Like Peptide-1 Receptor Agonist Use With Risk of Gallbladder and Biliary Diseases: A Systematic Review and Meta-analysis of Randomized Clinical Trials. JAMA Internal Medicine. 2022;182(5):513–519. doi:10.1001/jamainternmed.2022.0338
3 BMJ Best Practice (2024) Cholelithiasis (gallstones). BMJ Publishing Group. Available at: https://bestpractice.bmj.com/topics/en-gb/3000015 (Accessed: 23 October 2025).
Xyla is a trading name of ICS Operations Ltd (Registered No 4793945), Pulse Healthcare Limited (Registered No 3156103), Carehome Selection Limited (Registered No 3091598), Independent Clinical Services Limited (Registered No 4768329) and CHS Healthcare Software Limited (Registered No 11582111)